# Onvansertib in Combination With Gemcitabine and Nab-paclitaxel for the Treatment of Patients With Locally-advanced, Unresectable, or Metastatic Pancreatic Ductal Adenocarcinoma

> **NCT06398587** · PHASE2 · WITHDRAWN · sponsor: **OHSU Knight Cancer Institute**

## Conditions studied

- Locally Advanced Pancreatic Ductal Adenocarcinoma
- Metastatic Pancreatic Ductal Adenocarcinoma
- Stage II Pancreatic Cancer AJCC v8
- Stage III Pancreatic Cancer AJCC v8
- Stage IV Pancreatic Cancer AJCC v8
- Unresectable Pancreatic Adenocarcinoma

## Interventions

- **DRUG:** Onvansertib
- **DRUG:** Gemcitabine
- **DRUG:** Nab-paclitaxel
- **PROCEDURE:** Electrocardiography
- **PROCEDURE:** Magnetic Resonance Imaging
- **PROCEDURE:** Positron Emission Tomography
- **PROCEDURE:** Biospecimen Collection
- **PROCEDURE:** Biospecimen Collection
- **PROCEDURE:** Computed Tomography

## Key facts

- **NCT ID:** NCT06398587
- **Lead sponsor:** OHSU Knight Cancer Institute
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2024-08-01
- **Primary completion:** 2026-05-04
- **Final completion:** 2027-06-07
- **Target enrollment:** 0 (ACTUAL)
- **Why stopped:** Sponsor withdrawal
- **Last updated:** 2024-07-19

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06398587

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06398587, "Onvansertib in Combination With Gemcitabine and Nab-paclitaxel for the Treatment of Patients With Locally-advanced, Unresectable, or Metastatic Pancreatic Ductal Adenocarcinoma". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT06398587. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*